• Activating the patient’s immune system
    to fight cancer

Company presentations

Mesothelioma 24-month data

The 24-month data from the mesothelioma trial was released 10th June. For a video presentation, please see links below:

Q3 Third quarter 2021

Targovax ASA announced its third quarter 2021 results on Thursday November 4, 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.

Webcast presentation on Xtrainvestor

For a company presentation in Norwegian, please see video below.

Our strategy

Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor

Targovax has built on the previous immune activation and anti-tumor findings and showed that the combination of ONCOS-102 and Keytruda can generate systemic responses that reduce the size of non-injected lesions, i.e. abscopal anti-tumor effect. This work was performed in a humanized melanoma mouse model with tumors inoculated dorsally on both sides of the animals. After the tumors were established, ONCOS-102 was injected directly into the tumor on one side only, followed by systemic treatment with Keytruda. By Day 40, tumors on the non-injected side of the animals had shrunk by an average of 70%.

Mechanism of Action ONCOS-102

Targovax is developing a cancer immunotherapeutic technology with a targeted mechanism of action, making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-specific anti-tumor immune response. The lead clinical candidate is ONCOS-102.

TG Mutant RAS neoantigen vaccine – Available for partnering

Peptide-based neoantigencancer vaccines activate cancer specific T – cell immune-responses. Mutant RAS proteins are neoantigen and drivers for development of cancer. RAS mutations are exclusively found in cancer cells and are therefore cancer specific targets for attacking cancer immunologically.